Anacalypsis Therapeutics is a biotechnology company developing Parkinson's disease therapies, including a stapled peptide targeting the LRRK2-FADD interaction.
Anacalypsis Therapeutics secures pre-seed financing from Metavallon VC to advance its lead program, **AT-001**, and additional treatments targeting **Parkinson’s disease** and other neurodegenerative disorders. The funding supports early-stage development of its therapeutic pipeline, focusing on novel interventions for progressive neurological conditions.
Anacalypsis Therapeutics secures pre-seed funding from Metavallon VC to develop **AT001**, a first-in-class Parkinson’s disease therapy targeting the **LRRK2–FADD interaction**. The financing supports progression into a critical **in vivo efficacy study**, marking a key milestone for the Athens-based biotech’s lead program.
Anacalypsis Therapeutics secures €300,000 in pre-seed funding from Metavallon VC’s Brain Gain Fund to develop treatments for Parkinson’s disease and other neurodegenerative disorders. The Greece-based biotech company focuses on advancing research into novel therapies targeting these conditions. The funding supports early-stage development of potential new interventions.
Metavallon VC leads a €300K pre-seed round for **Anacalypsis Therapeutics**, a Greece-based biotech developing Parkinson’s disease treatments. The investment marks the first by a Greek VC fund into a local drug discovery biotech. Parkinson’s, the fastest-growing neurodegenerative condition globally, currently lacks approved therapies targeting its progression.
